Title |
Posterior reversible encephalopathy syndrome induced by anti-VEGF agents
|
---|---|
Published in |
Targeted Oncology, November 2011
|
DOI | 10.1007/s11523-011-0201-x |
Pubmed ID | |
Authors |
Camille Tlemsani, Olivier Mir, Pascaline Boudou-Rouquette, Olivier Huillard, Karin Maley, Stanislas Ropert, Romain Coriat, François Goldwasser |
Abstract |
Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiological entity that may occur in patients receiving anti-vascular endothelial growth factor (VEGF) agents such as bevacizumab and tyrosine kinase inhibitors. Little is known about the characteristics of patients at risk for PRES under anti-VEGF agents. We carried out a comprehensive review of reports documenting the occurrence of PRES in patients receiving anti-VEGF agents. Twenty-six patients are described with a majority of females (73.1%). Almost a third of patients had a past history of hypertension. The most common symptoms included headache, visual disturbance and seizure. A vast majority of patients had hypertension at the diagnosis of PRES, and proteinuria was detectable each time it was investigated. Neurological outcome was favorable in all cases with a symptomatic treatment including blood pressure control. The risk of PRES is increased when blood pressure is poorly controlled and when proteinuria is detectable. The clinical course appears favorable with a symptomatic treatment. PRES is a potentially severe but manageable toxicity of anti-VEGF agents. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Germany | 1 | 2% |
Unknown | 57 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 11 | 19% |
Other | 10 | 17% |
Student > Master | 7 | 12% |
Student > Postgraduate | 5 | 9% |
Student > Ph. D. Student | 3 | 5% |
Other | 9 | 16% |
Unknown | 13 | 22% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 30 | 52% |
Neuroscience | 3 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
Economics, Econometrics and Finance | 2 | 3% |
Nursing and Health Professions | 2 | 3% |
Other | 2 | 3% |
Unknown | 17 | 29% |